|Venture Round, 1/2013 |
The Texas Emerging Technology Fund
Admittance Technologies is committed to improving the quality of life of patients with heart disease through innovative electrical engineering solutions. Admittance will accomplish this goal through the application of CardioVol™, which can interrogate the heart with electric fields, and in real-time distinguish the blood and heart muscle components of these fields. They focus on the blood signal to warn patients of impending heart failure, maximize their hearts’ ejection of blood by properly tuning the pacing of these weakened hearts, and using stroke volume to determine if VT and rapid afib are hemodynamically unstable requiring defibrillation.